• In June 2023, The Lancet’s eClinicalMedicine journal published combined detailed analyses of Clene’s Phase 2 RESCUE-ALS study and its open-label extension trial
• In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises
• As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on top of many trade secrets
• Clene owns worldwide rights to commercialize its therapeutics but is looking for a partner to advance the MS indication

Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease, and multiple sclerosis (“MS”).

Its lead drug candidate is CNM-Au8(R), an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Longeveron’s study ELPIS I demonstrated 100% survival and heart transplant-free for up to 5 years of age
• All ten patients enrolled in the study were monitored for at least 3.5 years after treatment with Lomecel-B(TM), the company’s lead investigational product
• Longeveron’s study results show Lomecel-B(TM)’s potential, not just for the potential treatment of HLHS but also for Alzheimer’s disease and Aging-related Frailty

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, recently posted promising results from its ELPIS I clinical trial. Of note was data that showed that 100% of the ten patients who participated in the trial survived and remained heart transplant-free for up to 5 years of age after receiving the company’s lead investigational product, Lomecel-B(TM) (https://ibn.fm/TIOTm).

This study explored Lomecel-B(TM)’s potential to address hypoplastic left heart syndrome (“HLHS”), a congenital disability affecting normal blood flow through the heart. Historical results have shown that children with the condition have approximately 20% mortality by five years, with as many as 1,025, or one out of every 3,841 babies in the U.S. born with the condition (https://ibn.fm/gnCG7).

From the ELPIS I trial, all ten patients enrolled were monitored for at least 3.5 years after treatment with Lomecel-B(TM). To date, 5 out of the 5 eligible patients from the trial have already undergone the last of the three surgeries required to treat the condition, with Longeveron expected to present updated data from this process later in 2023.

“We are pleased to share additional long-term follow-up data demonstrating the continued survival of the ELPIS I trial participants,” noted Joshua M. Hare, M.D., Co-Founder, Chief Science Officer, and Chairman of the Board of Directors at Longeveron (https://ibn.fm/y8WmA).

ELPIS I is an open-label, Phase 1b trial specifically designed to evaluate the safety of Lomecel-B(TM) in patients with HLHS. Initial results demonstrated that the study met its primary safety endpoint and that all patients were alive, transplant-free, and maintained their expected growth rate one year after treatment. With these promising results, Longeveron is optimistic about the results to be shared later in the year. In addition, its management is excited for the next steps in the study, particularly as the company continues to enroll patients at the eight sites in the ELPIS II trial, a 38-patient, randomized (1:1) blinded, controlled Phase 2 clinical trial designed to evaluate the safety and efficacy of intramyocardial injection of Lomecel-B(TM) in infants with HLHS undergoing the Glenn Procedure.

“There is a major unmet need among children with HLHS, and today’s data highlighting the 100% survival rate of ELPIS I patients up to 5 years post-treatment underscore the potential opportunity for Lomecel-B(TM) as a much-needed therapeutic innovation for this patient group,” noted Sunjay Kaushal, M.D., Ph.D. Principal Investigator of the ELPIS I trial.

There is no FDA-approved medical treatment for HLHS, leaving a vast untapped market for Longeveron. So far, the product has received Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation from the United States Food and Drug Administration (“FDA”), which represent significant milestones for the company as it continues its work towards seeking FDA approval of Lomecel-B(TM) for HLHS.

 With these studies, the company looks to tap into several market opportunities, projecting that the potential market size for its Lomecel-B(TM) in treating HLHS could be up to $1 billion annually, globally. In addition, the company is investigating Lomecel-B(TM) to address Alzheimer’s disease, which represents a market between $5 billion to $10 billion annually, as well as Aging-related Frailty, which represents a market between $4 billion and $8 billion globally per year. 

For more information, visit the company’s website at www.Longeveron.com 

Forward-Looking Statements

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the company’s product candidates, and other positive results; the timing and focus of the company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the company’s product candidates; the company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the company’s ability to attract and retain such personnel; the company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the company’s results and forward-looking statements are disclosed in the company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

For more information, visit the company’s website at www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

• D-Wave is the world’s first commercial supplier of quantum computing solutions
• D-Wave’s customers have built quantum and quantum-hybrid applications in areas such as resource scheduling, mobility, logistics, drug discovery, portfolio optimization, manufacturing processes, and more
• Using D-Wave’s annealing quantum computing solutions, SavantX was able to increase deliveries per crane per day by 60% at Pier 300 at the Port of Los Angeles, one of the nation’s largest ports

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, is helping customers solve highly complex business problems today, helping to drive operational efficiencies, reduce costs, and increase revenue. By harnessing the power of its proprietary annealing quantum computing technology, D-Wave is able to address challenging optimization problems across a wide range of use cases, including logistics, drug discovery, resource scheduling, manufacturing processes and financial modeling.

The company’s pursuit of practical quantum computing has resulted in its technology being used by some of today’s most advanced enterprises worldwide, including numerous Forbes Global 2000 companies. In a September 11, 2023 interview with Bloomberg Technology, D-Wave CEO Alan Baratz said that he believes quantum technology “is going to fundamentally transform the way businesses operate and have a huge impact on the social and economic environment,” (https://ibn.fm/GG7zI).

One area where D-Wave’s quantum computing solutions have been applied successfully is logistics optimization at Pier 300 at the Port of Los Angeles, the nation’s largest facility for handling shipborne cargo. In 2021, the equivalent of more than 10 million 20-foot container units were transferred from ships to trucks to take them to their inland destinations. At a time when supply chains face increased disruptions, efficiency is key to ensuring the movement of goods keeps pace. Quantum computing can offer an important approach for identifying solutions to complex logistical problems like those faced by the port.

SavantX used D-Wave’s quantum technology to explore efficiencies at Pier 300, one of the port’s largest terminals, creating an application that demonstrated efficiency gains by optimizing equipment usage and personnel while ensuring that containers were cleared from the port as quickly as possible. SavantX saw a 60% increase in deliveries per crane per day using quantum computing for logistical optimization. (https://ibn.fm/hTOHg).

“Not all problems are optimization problems, but for the ones that are, there’s a huge opportunity to bring value into the equation,” said Ed Heinbockel, CEO of SavantX. “We’ve tasted the power of quantum, and we’re very, very excited about it.”

Demonstrating the capabilities of its quantum and quantum-hybrid solutions in solving real-world problems, D-Wave’s website features numerous customer success stories to show the impact its technology is having today (https://ibn.fm/9ZbAm).

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Capital marketers, insurance and wealth management experts, investment bankers, individual investors, and research analysts, are invited to attend the Dawson James Small Cap Growth Conference to be held in Wyndham Grand Harborside Jupiter, Jupiter, FL, October 12, 2023. The distinguished conference serves as a hallmark in the financial world, featuring important management experts slated to share cutting-edge innovations, strategies, and growth opportunities.

The highly anticipated 8th Annual Investor Conference provides a unique platform for evolving and established small-cap growth companies within the healthcare, technology, and consumer sectors. It’s a unique opportunity for ground-breaking businesses to showcase their products and services to a wide audience. The conference promises to provide ample networking opportunities to business owners who are eager to revolutionize the industry and deliver an enhanced ROI.

Promoting Investment Excellence

The Dawson James Small Cap Growth Conference will be dignified by a select, invite-only audience, that includes Institutional Funds, Family Offices, and a significant base of High Net Worth Accredited Investors. As an incredible blend of the brightest minds and opportunities, the conference aims to leverage the massive potential that small-cap growth companies offer. This rare gathering of professionals and extraordinary minds will explore a diverse range of investment prospects to set the tone for the day.

The core of the conference lies in the business presentations, where selected small-cap growth companies will take the stage. The conference will start at 7:30 a.m. with registration and a hearty breakfast to fuel participants for the exciting day ahead. Following the breakfast, a panel of eminent professionals will delve into the current investment setting, sharing valuable perspectives and insights into the growth potential and investment opportunities.  

Register today and be a part of small-cap growth and innovation.

Participating Companies as of 09/19/2023

• Aditxt, Inc. (NASDAQ: ADTX) (www.Aditxt.com) 
• Annovis Bio Inc. (NYSE American: ANVS) (www.AnnovisBio.com)
• bioAffinity Technologies, Inc. (NASDAQ: BIAF) (https://bioaffinitytech.com)
• Bitfarms (NASDAQ: BITF) (https://Bitfarms.com/)
• Borqs Technologies, Inc. (NASDAQ: BRQS) (www.Borqs.com)
• Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) (www.CitiusPharma.com)
• Clearmind Medicine Inc. (NASDAQ: CMND) (www.ClearmindMedicine.com)
• Cyclo Therapeutics (NASDAQ: CYTH) (https://cyclotherapeutics.com)
• CytoSorbents Corporation (NASDAQ: CTSO) (https://CytoSorbents.com)
• Dawson James Securities (https://DawsonJames.com)
• Digital Health Acquisition Corp. (NASDAQ: DHAC) (https://DigitalHealthAcquisition.com) 
• GeoVax Labs, Inc. (NASDAQ: GOVX) (www.GeoVax.com)
• HealthBeacon (OTCQX: HBCN) (https://HealthBeacon.com)
• Heartbeam, Inc. (NASDAQ: BEAT) (www.HeartBeam.com)
• Hillstream BioPharma, Inc. (NASDAQ: HILS) (https://HillstreamBio.com)
• Innovative Eyewear Inc, (NASDAQ: LUCY) (https://Lucyd.co)
• Inuvo Inc. (NYSE American: INUV) (https://Inuvo.com)
• JanOne, Inc. (NASDAQ: JAN) (https://JanOne.com)
• Janover Inc. (NASDAQ: JNVR) (https://JanOver.co)
• Kintara Therapeutics, Inc. (NASDAQ: KTRA) (www.Kintara.com)
• Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) (www.MatinasBiopharma.com)
• NextPlat Corp. (NASDAQ: NXPL) (www.NextPlat.com)
• NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (https://NovaBay.com)
• Neuro Rx Pharmaceuticals (NASDAQ: NRXP) (www.NRXPharma.com)
• Red Cat Holdings, Inc. (NASDAQ: RCAT) (https://RedCat.red)
• SeaStar Medical Holding Corp. (NASDAQ: ICU) (https://SeaStarMedical.com)
• SKYX Platforms Corp. (NASDAQ: SKYX) (https://SkyPlug.com)
• Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) (https://SonomaPharma.com)
• STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (www.StrataSkinSciences.com)
• Windtree Therapeutics, Inc. (NASDAQ: WINT) (https://WindtreeTX.com) 
• Wisa Technologies (NASDAQ: WISA) (www.WisaTechnologies.com)
• ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (www.ZIVOBioscience.com) 
• Zomedica Corp. (NYSE American: ZOM) (https://Zomedica.com)

Platinum Sponsors as of 09/19/2023

• ArentFox Schiff LLP (www.AFSLaw.com)
• Sicheniza Ross Ference Carmel LLP (https://SRF.Law)
• IBN (InvestorBrandNetwork) (www.InvestorBrandNetwork.com)
• IRTH Communications, LLC (www.IRTHCommunications.com)
• SLS Group (www.SLSGroup.io)
• The Money Channel (www.MoneyChannelNYC.com)

Other Sponsors as of 09/19/2023

• Core IR (https://CoreIR.com)
• Greenberg Traurig, PA (https://www.GTLaw.com/en/)
• Jaisin LLC (https://Jaisin.com/Los-Angeles/)
• Skyline Corporate Communications (https://SkylineCCG.com)
• Group, LLC (http://Group-LLC.com)
• The Nuvo Group, Inc (www.TheNuvoGroup.com)
• The Vendor Group (www.TheVendorGroup.com)
• Wall Street Reporting

To learn more, please visit https://ibn.fm/zNaw9

Educators, marketers, social media professionals, thought leaders, and research analysts, are invited to attend the Social Media Strategies Summit Higher Education to be held virtually on October 23-24, 2023, with an optional workshop October 25. The eminent summit aims to reshape the academic landscape with transformative insights, advanced strategies, and unmatched networking opportunities. The summit is committed to revealing the secrets of social media success as it brings together the brightest minds to reveal their unique strategies for growing online communities.

Rewriting the rules of social media promotion and engagement, the Social Media Strategies Summit Higher Education promises to lead the way in higher education transformation. The two-day event will be a game-changer for social media enthusiasts looking to harness the power of digital marketing. With a track record of providing insightful educational experiences, the Social Media Strategies Summit gives people the tools needed to achieve their goals.

Staying at the Forefront of Digital Transformation 

As institutions face the unique challenges of the modern world, the Social Media Strategies Summit Higher Education equips them with the latest insights needed to succeed. The summit will feature panel discussions and interactive sessions where professionals will share proven social media strategies and valuable real-world case studies to drive brand awareness, enrollment, and engagement.

Led by seasoned social media experts, these sessions focus on the art of content planning, data analytics, calendars, creativity, engagement, and more. Attendees will be engrossed with interactive activities, knowledge-sharing, short lectures with small breakout groups, and a chance to ask important questions. It’s a great opportunity for them to connect with solution providers, peers, and professionals in the higher education space. They can explore the latest technologies and share ideas in a learning and collaborative environment. 

Interested participants should enroll for the summit now and be a part of a community that is shaping the future of social media innovation.

Your ticket to the summit also unlocks access to the Corporate Brand Summit on October 26-27.

To learn more, please visit https://ibn.fm/m2yBG.

• Ucore Rare Metals Inc. is moving forward with a rare earth element (“REE”) processing facility in Louisiana that will help to establish an American base for the REE supply chain
• The REE supply chain is currently almost exclusively controlled by the People’s Republic of China thanks to China’s responsibility for 36.7 percent of the world’s REE reserves, 63 percent of REE mining capacity and more than 90 percent of REE refining capacity
• REE price increases this month as a result of temporary production shutdowns in Myanmar and China underscore the market’s sensitivity to supply interruptions resulting from governmental policies
• Ucore’s RapidSX(TM) solvent extraction process is being developed as an American-based alternative to the industry standard SX process for rare earth refining, and will be used in the Louisiana facility

This month’s shutdown of Myanmar rare earth mining to prepare for inspections sparked short-term stockpiling and upward pricing for metal products such as terbium oxide and dysprosium oxide used in solid-state devices, a reminder of the vulnerability of many tech device rare earth element (“REE”) components to sudden supply chain bottlenecks in Asian nations. It demonstrates how sensitive the REE industry is, and the potential threat posed by nations that dominate related supplies.

“Any extended shutdown of mining in Kachin could be quite damaging for Chinese refineries in Southern China which are reliant upon feedstock from Myanmar,” market analyst David Merriman stated in a Reuters report on the situation, and another analyst, Yang Jiawen, stated that similar environmental inspections in one of China’s major rare earth production hubs also helped fuel the price hikes and worries about supply disruptions (https://ibn.fm/GsPLe).

Because the People’s Republic of China provides a significant amount of REE mining and effectively monopolizes REE processing to extract the metals from mined ore, Western nations have been sounding alarms about their dependence on China’s supply chain and the control the Chinese government can wield over that supply chain.

China is responsible for 36.7 percent of the world’s REE reserves, 63 percent of its mining capacity and more than 90 percent of its refining capacity, according to a January report by Forbes (https://ibn.fm/Rw8Fl). The European Union imports 98 percent of its REE supply from China and the United States gets 78 percent of its supply from the Asian nation.

Canada-based critical technology metals supply chain innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is positioning itself to disrupt Chinese control of REE processing. The company has developed a proprietary REE processing technology it touts as an American improvement on the standard processing technology used throughout the industry and is preparing to commercialize its product by building a network of REE processing facilities, beginning with one in Louisiana it intends to begin work on later this year. 

The Louisiana Strategic Metals Complex [“SMC”] is scheduled to initially process 2,000 metric tons of total rare earth oxides by the end of 2024, increasing to 5,000 metric tons in 2026 (https://ibn.fm/DTTce). Additional SMCs are planned in the United States and Canada as the company grows.

Even with the price increases prompted by the temporary shutdown of processing facilities in Southeast Asia, the market price remains far below the startling peak prices reached just over a decade ago when China restricted exports. Neodymium, a rare earth necessary for products including headphones and hybrid electric cars, shot up from $18.5 per pound to $129 per pound at that time and Samarium, an essential element in missile manufacturing, rose from $8.5 per pound to $66 per pound, for example (https://ibn.fm/OtNBW).

But the skyrocketing prices in 2011 further underscore the importance of a diversified supply chain. Ucore’s preparations for building the Louisiana SMC, including demonstration of how its proprietary RapidSX(TM) solvent extraction process compares to the standard SX process at a Canadian facility, and financing measures that include a $4 million award from the U.S. federal government, are positioning the company to become a leader in domestic REE production in the near future.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis (ptosis), or low-lying eyelid
• Clinical studies have shown an average one-millimeter lift of the upper eyelid, with results in as little as five minutes post-dose
• UPNEEQ(R) is available through RVL Pharmaceuticals’ dedicated e-commerce platform, Elevate, which supports subscription ordering by HCPs and RVL Pharmacy patients
• RVL is poised to be an integral player in the global medical aesthetic market, which is estimated to reach $18 billion by 2027

RVL Pharmaceuticals (NASDAQ: RVLP), is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis (ptosis, or low-lying eyelids) in adults. The company believes there is significant potential for UPNEEQ(R) to create value for healthcare providers, patients, and shareholders.

“Looking ahead, we believe that UPNEEQ is a significant potential value driver,” noted Brian Markison, RVL’s CEO (https://ibn.fm/A1buv).

UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis, or low-lying eyelid. UPNEEQ(R) was approved in July 2020 and since its debut, medica professionals have been prescribing it for patients. UPNEEQ(R) has garnered significant media attention as well, having been featured in top-tier media outlets including Vogue, Elle, and Allure. Patients can purchase UPNEEQ(R) from eye care and medical aesthetic professionals or through RVL Pharmacy LLC, the company’s wholly owned pharmacy.

This once-daily eye drop has shown an average one-millimeter upper eyelid lift, improving appearance and the superior visual field in patients with a functional deficit. Clinical studies have also shown that patients’ eyelids lift in as little as five minutes post-dose, with the lift effect lasting as long as eight hours. This level of effectiveness presents a viable, more accessible, non-surgical alternative for patients with droopy eyelids, a unique value proposition only available with UPNEEQ(R).

Going forward, the company plans to drive adoption through Elevate, the company’s new e-commerce platform, which allows the company to offer subscription options and serve Business-to-Business-to-Consumer (“B-B-C”) clients.

“We expect that our future marketing mix will shift to the consumer to complement our personal selling efforts across the board,” noted Markison. “Conversions to Elevate, our new e-commerce platform, which is designated to enable us to offer subscription options to all our customers and a B-B-C program for direct purchasing locations, are off to an encouraging start.”

These significant strides will [help to] enable RVL to become a significant player in the medical aesthetics market, which is expected to reach $18 billion by 2027. The company is believed to be positioning itself to take advantage of this market growth, focused on providing an innovative, non-invasive solution to a common problem.

For more information, visit the company’s website at www.RVLPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP

• The global rare earth elements market is expected to grow from 167.99 million tons in 2023, and to 206.25 million tons by 2028 – growing at a CAGR of 4.19%
• Since starting the project, Appia has commenced diamond drilling in addition to its current reverse circulation and auger drilling campaigns
• Specimens from the drilling efforts will be submitted to SGS Geosol laboratory, with assays expected two months from submission

The global rare earth elements (“REE”) market is expected to grow from 167.99 million tons in 2023 to 206.25 million tons by 2028 – growing at a CAGR of 4.19%. The driving factors for the increase in REE production come from a global demand from emerging economies for “green technology” (https://ibn.fm/UuCTZ). With the high growth and demand, several companies are pursuing the REE industry, including Appia Rare Earths & Uranium (CSE: API) (OTCQX: APAAF), a mineral exploration company focused on exploration activities in Brazil and Canada. The company is funded no debt, and has an aggressive exploration program underway.

Appia’s newly acquired Cachoeirinha rare earths project (PCH Project) in Brazil represents important potential for the company. The PCH Project hosts REE mineralization in both ionic clays developed from the weathering of alkaline granites and in-situ rare earth mineralization associated with the area’s underlying granite and a carbonatite intrusion to depths greater than 100 meters. In July 2023, the company commenced an aggressive auger and reverse circulation drill campaign to delineate a potential resource estimate at the PCH Project.

The initial results from the PCH Project drill campaign revealed significant exploration potential and an impressive value that surpasses known ionic clay deposits in Brazil. Terbium and Dysprosium were among the highly valuable heavy rare earths the company uncovered.

In a press release following the July 2023 exploration, Appia CEO Tom Drivas said the company was thrilled with the progress made and the promising results thus far. “The company remains committed to advancing its exploration plans, aiming to promptly gather significant data throughout the year, and to work towards estimating a maiden mineral resource in the coming months,” Drivas added (https://ibn.fm/jYzRX).

Since then, Appia has deployed a third drill hole on-site at the PCH Project to investigate a significant geophysical anomaly at a depth below Target IV. The program was designed to expand on the diamond drilling that was completed in prior seasons. This additional drill hole brings Appia’s exploration of the PCH Project to include three drills – one auger, reverse circulation, and a diamond drill.

“The arrival of the diamond drill marks a pivotal advancement in our exploration initiative,” Appia President Stephen Burega said (https://ibn.fm/CZhSg). “It underscores our commitment to investigating not only the potential genesis of Ionic Adsorption Clay but also the exciting opportunity for REE mineralization in hard rock formations.”

The company’s primary objective is to accurately delineate the extent of mineralization and assess its economic significance. To achieve these efforts, Appia is employing a rigorous sampling procedure – including one-meter samples that will be carefully collected and shipped to SGS Geosol laboratory. Assays from the project are expected within two months from the submission of the specimens.

For more information, visit the company’s website at www.AppiaREU.com.

NOTE TO INVESTORS: The latest news and updates relating to APAAF are available in the company’s newsroom at https://ibn.fm/APAAF

• CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer
• CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’s end
• The company is also preparing the interim study analysis for release by year’s end, now that more than 50 percent of the planned patient roster has reached a point necessary for effective comparison of performance of the flagship drug, Berubicin, to that of a standard of care chemotherapy agent
• The company has stated that it took longer than anticipated to launch the interim analysis because many patients were living longer than historical expectations, and CNS hopes to show that Berubicin has helped patients achieve a longer Overall Survival (“OS”), driving eventual commercialization and improved treatments

Cancer drug developer CNS Pharmaceuticals (NASDAQ: CNSP) is closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”), with 200 of the expected 243 patients now enrolled in the company’s potentially pivotal study involving its flagship drug candidate Berubicin, according to a company news release (https://ibn.fm/OqKzk).

The Texas-based company has clinical trial sites operating in the U.S., Italy, France, Spain, and Switzerland, to evaluate Berubicin’s performance against standard of care alkylating chemotherapy agent Lomustine for treating recurrent GBM.

GBM has been generally untreatable by anthracyclines because of their inability to cross the blood-brain barrier, but Berubicin is believed to be able to cross the barrier and directly target central nervous system tumors.

CNS Pharmaceuticals’ progress in enrolling patients for its potentially pivotal, global clinical trial indicate the company is on track to not only complete enrollment by the end of the year, but also to issue its planned futility interim analysis by the end of the year.

The interim analysis was triggered when at least 50 percent of the enrolled patients had reached the pre-planned primary efficacy endpoint, allowing an independent Data Safety Monitoring Board (“DSMB”) to review the number of deaths in each arm of the trial to ensure that the overall survival of patients receiving Berubicin shows at least a statistically significant comparison to those receiving Lomustine.

The news release notes that Overall Survival (“OS”) is a rigorous endpoint that the U.S. Food and Drug Administration (“FDA”) has recognized as the basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm, and the DSMB’s review will consider making recommendations on whether to continue the study as planned or to modify it based on patient outcomes thus far.

CNS announced last month that it has taken longer than planned to reach the endpoint for launching the interim analysis because “many patients in this study are living longer than the historical data would suggest they should,” which means it took longer to reach the number of mortality events required to conduct the interim analysis (https://ibn.fm/5G4tw).

“As we have noted previously, patient volunteers and their treating clinicians are the backbone of our Berubicin development program. We are deeply sensitive to the fact that these brave patients are facing the battle of their lives and we are forever in their debt for the trust and confidence they and their treating clinicians have in Berubicin and the company,” CNS CEO John Climaco stated in the most recent company statement on enrollment. “We are pleased to achieve this landmark milestone. Importantly, this takes us one step closer to bringing the study across the finish line and potentially offering an effective treatment in GBM that is safe and well tolerated.”

Berubicin was originally produced by Reata Pharmaceuticals, Inc., in 2006, and a small-scale clinical trial testing Berubicin’s safety at the time produced statistically significant improvements in the two dozen patients, including one who has remained cancer-free during the ensuing years. CNS reached an agreement with Reata in more recent years to advance development of the drug, and launched the global trial in 2021.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• XESP, through its Digital Engagement Engine(TM), is making automation, powerful data management, and an advanced workflow, more accessible to B2B companies
• The company allows businesses to offer buyers meaningful and empowering experiences, making them feel appreciated and understood, and moving them to action
• XESP understands businesses’ concerns, especially regarding the cost of automation, and continues to refine its products, integrating new features and addressing emerging customer needs, all at a more competitive price point
• By integrating new features and making new offerings, the company is staying ahead of the competition and stamping its position as a leader in the digital activation and engagement space

Electronic Servitor Publication Network (OTCQB: XESP), a market disruptor for B2B companies, is showing how unique, cutting-edge data analysis and smart technology can grow businesses and help them develop a continuous flow of customers. Through its Digital Engagement Engine(TM), the company is making advanced marketing automation, data management, and an efficient marketing workflow, more accessible to B2B companies, affording them greater reach and lift for their digital content and ensuring greater customer satisfaction and advocacy.

“The Digital Engagement Engine(TM) isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.”

Experts in the industry have noted that automation is no longer an option. With changing customer demands and preferences, big and small businesses are all being forced to embrace new technologies and ways to satisfy these demands. XESP, through its Digital Engagement Engine(TM), offers a unique value proposition for its customers.

For starters, through its offering, XESP allows businesses to generate valued experiences that resonate with buyers. This comes in the form of more efficiently proving a brand’s end value to customers and delivering focused offerings that drive conversion and loyalty. Through its technological offerings, XESP can provide businesses with tools that allow customers to feel appreciated and heard. Superior intelligent automated technologies, when used correctly, are able to identify and respond meaningfully and immediately, addressing the growing need for customers to get a response in 10 minutes or less, a huge determinant of customer satisfaction (https://ibn.fm/M1Bah).

“That meaningful interaction gives a greater relationship with your audience and trust,” noted Peter Hager, XESP’s CEO. “Ultimately, it drives greater growth in your organization and, very simply put, replicates what you do face-to-face,” he added (https://ibn.fm/RRMha).

One of the biggest concerns for businesses is the cost of investing in certain conveniences, technologies, or product offerings. It is a legitimate concern since it counts as an ongoing expense for businesses looking to earn as much profit as possible from selling their products or services. XESP understands this concern, and while its offering is competitively priced, the bottom line is a significant return on investment, one that allows a business to meet their growth and return on investment objectives.

Studies on automation in businesses have validated its importance. For instance, with email and marketing automation, it was noted that for every $1 invested, businesses get $44 back. In addition, triggered emails resulted in eight times more opens and more significant sales than typical batch email sends. This is on top of offering an affordable way to stay connected with customers, an easier way to track and measure metrics, and the benefit of having a more efficient team.

XESP continues to refine its product, integrating new features and addressing emerging customer needs. The company’s understanding of the changing dynamics in the market allows it to stay ahead of the competition, offering products and services that solve real problems and deliver on its promise. This has helped set the company apart from its peers while positioning itself as a leader in its segment.

For more information, visit the company’s website at www.XESPN.com.

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP